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Available online 2 May 2008In vitro studies have attempted to identify dengue virus (DEN) target cells in peripheral blood; however,
extensive phenotyping of peripheral blood mononuclear cells (PBMCs) from dengue patients has not been
reported. PBMCs collected from hospitalized children suspected of acute dengue were analyzed for DEN prM,
CD32, CD86, CD14, CD11c, CD16, CD209, CCR7, CD4, and CD8 by ﬂow cytometry to detect DEN antigen in
PBMCs and to phenotype DEN-positive cells. DEN prMwas detected primarily in activated monocytes (CD14+,
CD32+, CD86+, CD11c+). A subset of samples analyzed for DEN nonstructural protein 3 (NS3) conﬁrmed that
approximately half of DEN antigen-positive cells contained replicating virus. A higher percentage of PBMCs
from DHF patients expressed prM, CD86, CD32, and CD11c than did those from DF patients. Increased
activation of monocytes and greater numbers of DEN-infected cells were associated with more severe dengue,
implicating a role for monocyte activation in dengue immunopathogenesis.
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The four serotypes of dengue virus (DEN1–4), members of the Fla-
vivirus genus of the Flaviviridae family, are positive-sense RNA viruses
(Lindenback and Rice, 2001). All serotypes can cause the full disease
spectrum of dengue, which ranges from undifferentiated febrile illness
to classic dengue fever (DF) to potentially fatal dengue hemorrhagic
fever (DHF) and dengue shock syndrome (DSS) (Burke and Monath,
2001). Severity of illness is classiﬁed according to the World Health
Organization (WHO) scheme, which incorporates several key clinical
manifestations including thrombocytopenia, bleeding, and signs of vas-
cular leak with and without associated hypotension (WHO, 1997). DEN
causes tens of millions of DF cases and hundreds of thousands of DHF/
DSS cases annuallyworldwide (GibbonsandVaughn, 2002;WHO,1997).
Although dengue affects the entire population, children bear the ma-
jority of theburdenof severe disease, asmore than90%ofDHF/DSS casesmjvargas81@yahoo.es
aubree@berkeley.edu
balmaseda@minsa.gob.ni
l rights reserved.occur in children less than 15 years of age (WHO,1997). Dengue activity
continues to increase,with over 60 countries reporting cases ofDHF/DSS
and more than 100 countries endemic for dengue, including most of
South and Southeast Asia, Central and South America, the Caribbean,
and South Paciﬁc regions (Halstead, 2002).
Secondary DEN infectionwith a different serotype from that which
caused primary infection has been identiﬁed as a major epidemiologic
risk factor forDHF/DSS (Burke et al.,1988;Halstead andYamarat,1965).
Halstead proposed that the presence of heterotypic anti-DENantibody,
induced by either previous heterotypic DEN infection or the transfer of
maternal antibody in infants, is not only unable to neutralize DEN, but
may actually increase viral load by opsonization and replication of
the virus in monocytes and macrophages, a phenomenon designated
as antibody-dependent enhancement (ADE) (Halstead et al., 1973;
Halstead and O'Rourke, 1977). ADE of DEN infection has yet to be
deﬁnitively demonstrated in vivo in humans, although higher levels of
viremia in dengue patients have been correlated with increased
disease severity (Murgue et al., 2000; Vaughn et al., 2000). It is unclear
whether or not monocytes/macrophages are the primary target cell of
DEN, as it is difﬁcult to infect these cells in vitro in the absence of
antibody (Kou et al., 2008), and other cell types such as dendritic cells
(DCs) are more susceptible to DEN (Jessie et al., 2004; Marovich et al.,
Table 1
Mean percentage of DEN antigen (prM) in live PBMCs stratiﬁed by surface marker
Cocktail 1
DEN
prM
antigen
CD86+
and
prM
CD86−
and
prM
CD209+
and
prMa
CCR7+
and
prMa
CD83+
and
prMa
CD16+
and
prMa
% of total live PBMCsb 11.2±
1.8
9.2±
1.9
2.0±
0.3
1.3±
0.2
2.1±
0.2
0.5±
0.1
6.3±
0.4c
% of live
prM-containing cells
100 82.2 17.8 11.6 18.8 4.5 56.2
Cocktail 2
DEN
prM
antigen
CD32+
and
prM
CD32−
and
prM
CD14+
and
prMd
CD11c+
and
prMd
CD4+
and
prMd
CD8+
and
prMd
% of total live PBMCsb 10.5±
1.8
7.9±
1.7
2.2±
0.3
7.2±
1.6
9.3±
1.6
0.4±
0.1
1.0±
0.1
% of live
prM-containing cells
100 78.2 21.8 71.3 92.1 4.0 9.9
a Includes both CD86+ and CD86− cells positive for the indicatedmarker and DENprM.
b ± standard error (SE).
c 2.4% live cells CD86+/CD16+ cell, 3.9% live cells CD86−/CD16+ cells.
d Includes both CD32+ and CD32− cells positive for the indicatedmarker andDENprM.
430 A.P. Durbin et al. / Virology 376 (2008) 429–4352001; Wu et al., 2000). Early reports described DEN infection of
peripheral blood leukocytes in DHF patients but did not rigorously
identify the target cells (Scott et al., 1980; Waterman et al., 1985). In a
limited analysis, King et al. (1999) identiﬁed replicating DEN primarily
in B cells as well as monocytes, NK cells, and T cells from DHF patients.
Dengue antigenwas detected by immunohistochemical (IHC) staining
in the Kupffer cells of the liver, splenic lymphoid cells, alveolar mac-
rophages, and renal tubular cells in biopsies obtained pre- and post-
mortem fromDHF/DSS patients (Jessie et al., 2004). Blood clots from 8
of 20 dengue patients revealed DEN antigen primarily in peripheral
monocytes, but also in some lymphocytes. Only splenic lymphoid cells
and peripheral blood monocytes (and some lymphocytes) were posi-
tive for DEN antigen by in situ hybridization in 7 of 8 of these patientsFig.1.DENantigendetection in CD32+ and CD32− populations of PBMCs. Sampleswere stained
CD4-PECy7, CD8-APC-Cy7, 2H2-Alexa488 and a live–deadmarker. Samples were ﬁrst gated o
presence of DEN antigen (prM) using mAb 2H2. DEN antigenwas found primarily in CD32+ PB
Themajority of DENantigen found in CD32+ gate is present in CD14+ and CD11c+ cells. (B) Repr
DEN antigen in the CD32− gate is present in CD11c+ cells.(Jessie et al., 2004). However, studies to date have detected DEN
structural proteins or positive-strand viral RNA, which may indicate
phagocytosis of the virus and not necessarily active replication.
In this pilot study, we evaluated peripheral blood mononuclear
cells (PBMCs) recovered from pediatric DF and DHF cases for the
presence of DEN antigen and compared the phenotypic markers of
DEN-infected cells from these two patient populations. Using mono-
clonal antibodies to both structural and nonstructural DEN proteins,
we found that activated monocytes (CD86+, CD32+, CD14+, CD11c+)
were themain target of DEN infection regardless of immune status.We
also observed signiﬁcantly increasedmonocyte activation (CD86+) and
a higher prevalence of CD32+, CD14+, CD11c+, and DEN prM+ cells in
DHF patients compared with DF patients, which has implications for
ADE and the immunopathogenesis of DHF.
Results
This study attempts to characterize differences in the PBMC pop-
ulations of DF and DHF patients and to determine which cell types
contain signiﬁcant amounts of DEN antigen. Sufﬁcient viable PBMCs
were recovered and analyzed from 14 children hospitalized with acute
DF and from 4 children hospitalized with DHF. All DHF patients had
serologic evidence of a secondary DEN infection, compared to 10 of
the 14 DF patients. Eighty-seven percent of samples had a viability of
greater than50%by live–deadmarker. Therewasnocorrelationbetween
viability and expression of prM or disease severity (data not shown).
Virus serotype was identiﬁed by virus isolation and/or RT-PCR from the
blood of all but four patients (three DF patients and one DHF patient),
yielding 11 DEN2 and 3 DEN1 infections.
Cell types expressing DEN antigen
Two cocktails of monoclonal antibodies (mAbs) were utilized to
detect DEN antigen in the PBMCs of hospitalized dengue patients and to
phenotype those cells positive for DEN antigen. DEN prM antigen was
detected in approximately 11% of all live PBMCs (Table 1). Because of the
different scatter and size characteristics of monocytes and lymphocyteswith a cocktail containing the conjugatedmAbs CD32-PE, CD14-PerCPCy5.5, CD11c-APC,
n CD32+ cells and CD32− cells, and populations within those gates were examined for the
MCs. (A) Representative sample of the prM-positive populations within the CD32+ gate.
esentative sample of the prM-positive populationswithin the CD32− gate. Themajority of
Fig. 2. DEN antigen detection in CD86+ and CD86− populations of PBMCs. Samples were stained with a cocktail containing the conjugated mAbs CD86-PE, CD209-PerCPCy5.5, CD83-
APC, CCR7-PECy7, CD16-APC-Cy7, 2H2-Alexa488, and a live–deadmarker. Sampleswere ﬁrst gated on CD86+ cells and CD86− cells, and populationswithin those gateswere studied for
the presence of DEN antigen (prM) using mAb 2H2. DEN antigen was found primarily in CD86+ PBMCs. (A) Representative sample of the prM-positive populations within the CD86+
gate. Only a small percentage of CD86+ cells containingDENantigen expressed CD209, CCR7, or CD16. (B) Representative sample of the prM-positive populationswithin the CD86− gate.
The majority of DEN antigen in the CD86− gate is present in CD16+ cells.
431A.P. Durbin et al. / Virology 376 (2008) 429–435in ﬂowcytometry, gatingwas initially performed based onmorphology;
it was then observed that the greatmajority of DEN antigen-positive live
PBMCs were CD86+ (82%) in cocktail 1 and CD32+ (78%) in cocktail 2
(Table 1). Since these cell surface markers distinguish predominately
monocyte/macrophage populations more reliably than morphological
characteristics alone, subsequent analyses were performed on CD32+
and CD32− cells (cocktail 2) and CD86+ and CD86− cells (cocktail 1)
separately. DEN antigen was detected primarily in cells that were
phenotypically monocytes (CD14+, CD32+) and not lymphocytes (CD4+,
CD8+) (Table 1, Fig. 1). Cells positive for DEN antigen in cocktail 2 were
also substantially positive (92%) for CD11c (iC3b receptor) (Table 1,
Fig. 1A). The proportion of PBMCs expressing CD32 was signiﬁcantly
associated with the proportion of DEN prM-positive live cells (p=
0.0005). Approximately 2% of all live cells were CD32−/prM+ (Table 1,
Fig. 1B); these cells were additionally positive only for CD11c.
The majority (82%) of live cells stained with cocktail 1 containing
DEN prM expressed CD86 (B7-2) (Table 1, Fig. 2A); these cells were not
positive for the mature DC marker CD83. Although CD209 expression
was detected at a low rate in cells positive for DEN antigen (Table 1,Fig. 3.DENprMandNS3detection inPBMCs. Sampleswere stainedwith a cocktail containing the
patient sample stained for DEN prM andDENNS3. Total PBMCs stainedwith anti-DEN prMmAb
(right), with isotype control (left). DEN NS3was detected in approximately 49% of prM+ cells. (B)
with anti-CD14mAb (vertical axis) and anti-DENNS3mAb (horizontal axis) from representative
predominantly (85%) in CD14+ cells. Extensive analysis of other markers expressed by cells conFig. 2A), the CD86+ cells expressing CD209 were signiﬁcantly asso-
ciatedwith those cellswith detectable DENantigen (p=0.0015). CD209
expression was not detected in prM-negative samples. CD16 (Fcγ re-
ceptor III)-expressing cells that contained DEN antigen were distrib-
utedbetween CD86-positive (2.4%) andCD86-negative live cells (3.9%).
Only a small percentage of CD86+/prM+ cells expressed CCR7 (DC
homing/trafﬁcking chemokine, Table 1). Approximately 2% of live cells
stained with cocktail 1 were CD86−/prM+ (Table 1, Fig. 2B); these cells
were negative for all other markers in cocktail 1 except for CD16.
Because of the limited number of markers that could be studied, no
speciﬁc B cell or NK cell marker was included in either cocktail.
Overall, DEN antigen was primarily detected in cells that were
phenotypicallymonocytes: CD86+, CD32+, CD14+, CD11c+, CD83−, CD4−,
CD8−, CD209−. However, a small percentage of prM-positive cells did
express CD209. In addition, a population of cells containing DEN
antigen did not express CD86, lymphocyte markers CD4 or CD8, or
monocyte markers CD14 or CD32. They did, however, express CD16
(cocktail 1) or CD11c (cocktail 2). These cell populationsmay represent
NK cells (CD86−/CD16+) and dendritic cells (CD32−/CD14−/CD11c+).conjugatedmAbsCD14-PerCPCy5.5, 2H2-APC, andNS3-PE. (A) PBMCs fromrepresentative
(vertical axis) and anti-DENNS3mAb (horizontal axis) from representative patient sample
Representative sample of PBMCs stained for both DENNS3 and CD14. Total PBMCs stained
patient sample (right), with isotype control (left). DEN NS3+ detected in PBMCswas found
taining detectable NS3 was not performed due the limited availability of samples.
Fig. 4. Comparison of cell populations identiﬁed by cellular marker in DHF versus DF
patients. Signiﬁcance was determined by Students t test and was determined for DHF
and DF cases only. PBMCs fromDHF patients contained signiﬁcantly greater populations
of CD86+, CD32+ CD14+, and CD11c+ cells than did those frompatients diagnosedwith DF.
In addition, signiﬁcantlymoreDENantigenwas detected in the PBMCs of DHF patients as
compared to DF cases. Black bars: DHF cases; speckled bars: DF cases; striped bars:
dengue-negative controls. Error bars represent the standard error of the mean.
432 A.P. Durbin et al. / Virology 376 (2008) 429–435To restrict the analysis to replicating virus only, analysis with anti-
NS3mAbswas performed on samples from a subset of 11 patients (7 DF,
4 DHF) fromwhom sufﬁcient cells were available. NS3 was detected in
samples from all patients. Overall, 3.4%±0.8% (standard error) of total
PBMCs were NS3-positive (see Fig. 3A for a representative sample),
compared with prM detection in 4.5%±0.9% of PBMCs in this limited
analysis. Although only a restricted analysis of the cell type inwhichNS3
was detected could be performed, NS3 was detected primarily (85%) in
CD14+ cells (Fig. 3B). In a cumulative analysis of all samples, 79.6%±2.8%
of PBMCs with detectable NS3 antigen expressed CD14.
Comparison of the phenotype of cells from DF and DHF patients
The expression of CD86, CD83, CD209, CCR7, CD16, andDENprMwas
analyzed in 20 serial samples recovered from 14 DF patients and in 9
serial samples recovered from 4 DHF patients. Ten samples from 4 DHF
patients and 15 samples from 12 DF patients were analyzed for the
expression of CD4, CD8, CD32, CD14, CD11c andDEN prM. Samples from
two febrile patients who were subsequently conﬁrmed as negative for
DEN infection were included for comparison. Overall, no signiﬁcant
differencewas found in the expression of CD4, CD8, CCR7, CD83, or CD16
in PBMCs recovered frompatientswithDHF compared toDF. However, a
signiﬁcant increasewasobserved in the expressionof CD86, CD32, CD14,
CD11c, and DEN prM in PBMCs from DHF patients compared with DF
patients (Fig. 4). For instance, a signiﬁcantly higher percentage of DEN
antigen containingPBMCs fromDHFpatients expressedCD32 compared
with those from DF patients (43.7%±3.3 vs. 31%±2.7, α=0.01); likewise
for CD86 (35.0±3.8 vs. 19.8±2.4, α=0.01). Samples from two dengue-
negative patients were included in these experiments as negative con-
trols. Signiﬁcance testing was not performed on the negative-control
samples because of the limited number of patients; however, the ex-
pression of surfacemarkers on PBMCs from these patients is included in
Fig. 4 for comparison. No signiﬁcant differences were detected with any
marker in relation to immune status (primary versus secondary DEN
infection) or when stratiﬁed by infecting virus serotype. When primary
DEN infections were removed from the analysis, the difference in the
expression of CD86, CD32, CD14, CD11c, and DEN prM remained sig-
niﬁcant between DHF and DF patients.
Discussion
Monocytes and macrophages have long been considered the pri-
mary target cells of DEN infection, although the recovery of DEN or
DEN antigen from monocytes of dengue patients has met with var-
iable success (Halstead et al., 1977; Jessie et al., 2004; King et al., 1999;
Morens et al., 1991; Scott et al., 1980; Waterman et al., 1985). To date,
DEN antigen has been recovered from mixtures of peripheral blood
cells, but the target cells in infected humans have not been deﬁned by
detailed phenotypic characterization. Other purported target cells of
DEN include immature DCs in skin and lymph nodes (Kyle et al., 2007;
Marovich et al., 2001; Wu et al., 2000). In this initial study, we char-
acterized the phenotype of PBMCs from acute pediatric dengue
cases using mAbs to both structural and nonstructural DEN proteins
together with two mAb cocktails staining for numerous cellular
markers, including DC-SIGN (purported co-receptor for DEN, Tassa-
neetrithep et al., 2003). We found the vast majority of cells containing
DEN antigen expressed the phenotype typical of activated periph-
eral blood monocytes, even in primary DEN infections. In a limited
analysis, we demonstrated that replicating DEN virus, as evidenced by
the presence of NS3 protein, was found predominantly in CD14+ cells.
Finally, we found that expression of CD86, CD32, CD14, CD11c, and
DEN prM was signiﬁcantly increased in PBMCs from DHF patients as
compared with DF patients.
When stained simultaneously by mAbs directed to structural and
nonstructural DEN proteins, approximately half of those cells that
containedDENprMproteinwere alsopositive forNS3. The lower level ofNS3 detection is not unexpected, for several reasons. First, prM will be
detected intracellularly in both infecting virions as well as replicating
genomes,whereasNS3derives only from replicatinggenomes. Thus, it is
likely that NS3 is more difﬁcult to detect by intracellular staining and
may sometimes be below the limit of detection. Second, a greater
number of monocytes would be expected to contain residual phagocy-
tosed DEN antigen than to be supporting active viral replication.
Nonetheless, the detection of NS3 primarily in CD14+ cells demonstrates
that monocytes are targets of DEN infection and active replication in
vivo. Approximately 20% of cells with detectable NS3 were CD14−,
indicating that viral replication is occurring to a much lesser extent in
cells other thanmonocytes. These cellsmay represent B cells (King et al.,
1999), dendritic cells, or possibly NK cells.
Two small subpopulations staining with DEN antigen were not
characteristic of monocytes. The ﬁrst (CD86−/CD16+, cocktail 1; CD32−/
CD11c+/CD4−/CD8−, cocktail 2) may represent NK cells; however,
because of the limited number of cells available for staining, NK cell
marker CD56 was not included in the analysis. The second
subpopulation was comprised of DC-SIGN-positive cells. CD14+ DC
precursors (preDC), which also express DC-SIGN, have been derived
from CD34 progenitor cells and are thought to be closely related to
dendrocytes (Kwan et al., 2005). In addition to CD14 and DC-SIGN,
these cells express CD86, CD11c, and CD32 and support DEN infection
and replication, albeit less effectively than DCs (Kwan et al., 2005).
Although DEN infects interstitial CD14+ cells less efﬁciently than
Langerhans cells, these CD14+ cells are more numerous in the skin and
may provide a greater opportunity for DEN cell entry and replication
via binding to DC-SIGN (Kwan et al., 2005). Interestingly, CD14+/CD1a−
monocyte-derived DC precursors are refractory to DEN infection (F.B.
dos Santos, C.M. Mueller, and E. Harris, unpublished). Whether or not
the small numbers of DC-SIGN+ cells that were found to contain DEN
antigen represent preDCs or monocyte-derived dendritic cells could
not be determined in this study, as there were not sufﬁcient cells to
stain for DEN antigen, CD14, and DC-SIGN together in a separate
cocktail.
Importantly, signiﬁcantly higher percentages of DEN antigen-
positive cells from DHF patients expressed CD32, the FcγII receptor
on monocytes, as compared to DF patients. In vitro studies have
demonstrated that although peripheral blood monocytes are infected
poorly by DEN, non-neutralizing antibody greatly enhances infection
(Halstead et al., 1973; Halstead and O'Rourke, 1977) by forming im-
mune complexes with the virus and enabling its entry via the FcγII
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development of more severe disease in secondary DEN infections
(Kliks et al., 1989), and in vitro studies as well as passive antibody
studies in non-human primate models have substantiated the
potential role of ADE in enhanced viremia (Goncalvez et al., 2007;
Halstead, 1979). In addition, interferon (IFN)-γ, the levels of which are
signiﬁcantly increased in the serum of DEN-infected patients in the
acute phase of illness (Azeredo et al., 2001; Green et al., 1999b; Kurane
et al., 1995; Kurane et al., 1991), may contribute to increased entry
of DEN into monocytes through higher numbers of FcγII receptors
(Kontny et al.,1988; Rothman and Ennis,1999). Although absolute viral
load was not measured in patients in this study, DEN antigen was
detected in a higher proportion of PBMCs fromDHF patients, and there
was a signiﬁcant correlation between the proportion of CD32-positive
cells and cells positive for DEN antigen in these samples (p=0.0005).
CD86 was also detected in a higher proportion of PBMCs from
DHF patients, as compared with DF. CD86 (B7-2) is a costimulatory
molecule important for the activation of T cells and is upregulated on
antigen-presenting cells such as monocytes, macrophages, DCs, and B
cells following stimulation and interaction with CD28 (Bhatia et al.,
2006; Reiser and Stadecker, 1996). IFN-γ, presumably from activated T
cells (Kurane et al., 1991), also increases the expression of CD86 on
monocytes (Creery et al., 1996). The signiﬁcantly higher levels of CD86
expression in DHF patients may therefore be a result of increased
antigen load and activation, a consequence of upregulation by IFN-γ,
or a combination of the two. Elevated levels of cytokines have been
detected in DHF/DSS patients and may play a causal role in the vas-
cular leak and coagulopathy syndromes characteristic of severe den-
gue (Bethell et al., 1998; Green et al., 1999a; Hober et al., 1996; Hung
et al., 2004; Kurane and Ennis, 1994; Pinto et al., 1999). Speciﬁcally,
elevated levels of TNF-α, which is produced by activated monocytes
and DCs (Chaturvedi et al., 1999), are associated with more severe
dengue in patients (Azeredo et al., 2001; Hober et al., 1996; Hung et al.,
2004) and increase vascular permeability in in vitro (Dewi et al., 2004)
and in vivo models (Atrasheuskaya et al., 2003; Shresta et al., 2006) of
DEN infection. Although we did not speciﬁcally measure TNF-α levels
in these patients, the upregulation of CD32, CD11c, and CD86 is in-
dicative of monocyte activation, and patients with DHF demonstrated
evidence of greater monocyte activation than did those with DF. Our
data is thus consistent with a model inwhich a feedback loop initiated
by elevated levels of IFN-γ produced by cross-reactive T cells induces
the expression of CD32 on peripheral blood monocytes (Kurane and
Ennis, 1992). Antibody–virus complexes, via the FcγII receptor, gain
entry intomonocytes,where viral replication and antigen load result in
activation and increased expression of CD32 and CD86, allowing for
even greater viral entry. The release of immunomodulatory cytokines,
including TNF-α, from activated monocytes then contributes to in-
creased permeability across endothelial cells and the hallmark vas-
cular leak syndrome. Eventually, the virus is cleared and the feedback
loop is abrogated.
Although our results suggest a role for monocyte activation in DHF,
the study had several limitations. Because the amount of blood that
may be safely drawn from acutely ill pediatric patients is small, only a
limited number of PBMCs were available for analysis. For this reason,
wewere unable to determine if DEN antigenwas present in NK cells or
B cells or if the DEN antigen detected in other cell populations
represented replicating virus. B cell infection and activation by DEN
cannot be excluded in this study because B cells can express both CD86
and CD32. DEN virus has been isolated from B cells obtained fromDHF
patients and may be an important target cell during infection (King et
al., 1999). Because the study was limited to phenotyping of cells
expressing DEN antigen, intracellular staining of IFN-γ or other
cytokines was not performed. However, as described above, other
studies have implicated IFN-γ in the upregulation of CD32. Finally, we
were not able to compare NS3 and prM expression directly in each of
the samples analyzed.Nonetheless, this initial in vivo phenotyping study was able to sub-
stantiate monocytes as the predominant target cell in the peripheral
blood of dengue patients. Importantly, this demonstrates that DEN tar-
gets the same cell type in PBMCs in both primary and secondary in-
fections. In addition, our data supports a role for activatedmonocytes in
the immunopathogenesis of DEN. These studies are being extended to
further evaluate the activation phenotype of peripheral blood mono-
cytes following DEN infection via intracellular cytokine staining, to fur-
ther characterize the identity of DC-SIGN-positive cells, to explore the
possible role of peripheral blood NK cells and B cells in DEN infection,
and to further characterize thephenotypeof cells in theperipheral blood
that are supportive of active DEN replication.
Materials and methods
Study design and population
PBMCs were obtained from an ongoing study at the Infectious
Disease Unit of the Hospital Infantil Manuel de Jesús Rivera (HIMJR),
the Nicaraguan National Pediatric Reference Hospital in Managua.
Suspected dengue cases that presented to the HIMJR within 4 days
since onset of fever between August, 2005 and February, 2006 and
who completed the required informed consent and assent proce-
dures were enrolled. Study participants included 15 females and 13
males 7 to 14 years old. Twenty-six patients were laboratory-con-
ﬁrmed as positive for DEN infection and 2 as dengue-negative; of the
conﬁrmed dengue cases, 6 (23%) were classiﬁed as DHF and 20 (77%)
were diagnosed as DF. Seven cases (27%) were deﬁned as primary
and 19 cases (73%) as secondary DEN infections. The serotype was
determined in 20 cases (77% of positive cases), with 4 DEN1 and 16
DEN2 infections.
Serological and virological assays to detect DEN infection were
performed at the National Virology Laboratory of the Ministry of
Health in Managua. A positive case was deﬁned by IgM seroconver-
sion, a 4-fold or greater increase in total anti-DEN antibodies as
measured by Inhibition ELISA (Balmaseda et al., 2006; Fernandez and
Vazquez, 1990), detection of viral RNA by RT-PCR, and/or virus
isolation (Hammond et al., 2005; Harris et al., 2000). In accordance
with the WHO classiﬁcation scheme, DHF was deﬁned as fever with
hemorrhagic manifestations, thrombocytopenia, and hemoconcentra-
tion or elevated hematocrit for age and sex or other signs of plasma
leakage (e.g., pleural effusion, ascites); DSS was deﬁned as DHF plus
either hypotension for age (systolic pressure b80 mmHg for those
b5 years of age and b90 mmHg for those N5 years of age) or narrow
pulse pressure (b20 mmHg) in the presence of clinical signs of shock
(e.g., slow capillary ﬁlling, cold clammy skin) (WHO, 1997). Primary
and secondary DEN infections were deﬁned by an antibody titer
by Inhibition ELISA of b2560 or N2560 in convalescent samples, re-
spectively (Harris et al., 2000). This study was approved by the
Institutional Review Boards at the University of California Berkeley,
the Nicaraguan Ministry of Health, and the HIMJR.
PBMC preparation
Daily blood specimens were obtained from patients (average 2.2
samples, range 1–4), along with a convalescent/discharge sample.
Analyzed samples were obtained 4, 5, or 6 days following the onset
of symptoms (mean of 4.9±0.2 days). Six milliliters of blood were
collected in CPT tubes (Becton-Dickinson, Franklin Lakes, NJ); the
transport temperature (∼28 °C), time of sample collection, transport,
reception, and processing (total=∼2.5 h) were strictly controlled
using personal data assistants (PDAs) with barcode scanners. Upon
receipt in the National Virology Laboratory, the tubes were cen-
trifuged for 30 min at 765 ×g at room temperature. The cells and
plasma were mixed by inversion, centrifuged for 15 min at 340 ×g,
the plasma was removed, and the cell pellet was washed with RPMI
434 A.P. Durbin et al. / Virology 376 (2008) 429–4351640 (Gibco/Invitrogen, Carlsbad, CA) containing 2% FBS (Hyclone,
Logan, UT) and 1% penicillin/streptomycin and centrifuged for 15min
at 340 ×g. The supernatantwas discarded, the pellet was resuspended
in 10 mL of RPMI 1640 with 2% FBS and 1% penicillin/streptomycin,
cells were counted, and 5 mL was removed for use in another study.
The remaining 5 mL were centrifuged for 15 min at 340 ×g and
resuspended in the volume of 90% FBS/10% dimethyl sulfoxide cal-
culated to result in a ﬁnal concentration of 5×106 cells/mL. Average
yield was 7.2×106 cells (range 1.4–29.5×106). Cryovials containing
the cell suspensionwere placed in isopropanol containers (Mr. Frosty,
Nalgene, Rochester, NY) at −80 °C overnight and then transferred to
liquid nitrogen.
Monoclonal antibodies
Monoclonal antibody (mAb) hybridoma clone D3-2H2-9-21,
which recognizes the prM protein of all four DEN serotypes, was
purchased from the American Type Culture Collection (Manassas,
VA). MAb was produced from the D3-2H2-9-21 clone at Biovest
International, (Minneapolis, MN) and conjugated to Alexa-488 at
Molecular Probes (Eugene, OR). 2H2-Alexa-488 was used at a ﬁnal
dilution of 1:600. A premixed cocktail of conjugated mAbs CD86-PE,
CD83-APC, and CD209-PerCP Cy5.5, individual conjugated mAbs
CCR7-PE-Cy7, CD16-APC-Cy7, CD4-PE, CD8-APC-Cy7, CD32-PE, and
CD14-PerCP Cy5.5, CD3-PacBlue, and all isotype controls were pur-
chased from BD Biosciences (San Jose, CA). CD11c-APC was obtained
from Invitrogen (Carlsbad, CA). Anti-NS3 mAb was generated pre-
viously in the Harris laboratory (P.R. Beatty and E. Harris, unpub-
lished results).
Flow cytometry
Samples were analyzed on a Becton-Dickinson FACSAria ﬂow
cytometer (San Jose, CA). Cryovials were removed from liquid
nitrogen, rapidly thawed in a 37 °C water bath, and transferred to
a 15-mL tube containing Hank's Buffered Saline Solution HBSS
(Cambrex Bio Science, Walkersville, MD). The tubes were centrifuged
for 8 min at 300 ×g, and the cell pellet was resuspended in 1 mL
PBS (Cambrex Bio Science). One microliter of ﬂuorescent live–dead
marker (Molecular Probes) was added to 1×106 cells and mixed well.
After a 30-minute incubation on ice, cells were washed with PBS
and incubated for 20 min on ice with blocking buffer consisting of
10 μg/mL human IgG (Sigma Chemical Co., St. Louis, MO) in staining
buffer (3% heat inactivated fetal calf serum [Atlantic Biologicals,
Atlanta, GA] in PBS, pH 7.4–7.6). Then 250,000–300,000 cells were
transferred into 12×75 mm tubes (Evergreen Scientiﬁc, Los Angeles,
CA), ﬁxed and permeabilized with Cytoﬁx/Cytoperm solution (BD
Biosciences), and incubated at 4 °C for 30 min with conjugated mAb
2H2-Alexa-488 at a ﬁnal dilution of 1:600. Cells were washed twice
in Perm/Wash buffer (BD Biosciences) and resuspended in 75 μL of
staining buffer containing either mAb cocktail 1 (CD86-PE, CD83-
APC, CD209-PerCP Cy5.5, CCR7 PECy7, and CD16-APC) or cocktail 2
(CD4-PECy7, CD8-APC-Cy7, CD32-PE, CD14-PerCP Cy5.5, and CD11c-
APC). Anti-NS3 mAb was conjugated to phycoerythrin using the
Zenon IgG labeling kit (Invitrogen). Samples were stained with cock-
tail 1 and, if sufﬁcient cells were present, were also stained with
cocktail 2.
Samples were read in a FACSAria ﬂow cytometer within 3 h of
staining. Isotype controls were included in each run. In addition, a
sample from a patient hospitalized with suspected dengue but
who was negative for DEN infection by serology and virus isola-
tion was included in the experiments staining with cocktail 1 and
cocktail 2. There were not sufﬁcient cells available from dengue-
negative patients for inclusion in the experiments staining for
NS3. Compensation was optimized using BD CompBeads (BD Bio-
sciences). The percentage of live cells expressing each surfacemarker contained in an individual cocktail was ﬁrst determined.
Analysis of live cells was performed by ﬁrst gating on CD86-positive
and CD86-negative cells (cocktail 1) or CD32-positive and CD32-
negative cells (cocktail 2) and studying the subpopulations with-
in each gate to determine which were positive for DEN antigen.
Staining with anti-NS3 antibody was performed on the subset of
samples with sufﬁcient PBMCs to speciﬁcally identify replicating
virus. The NS3-PE antibody was included in a cocktail containing
2H2-APC and CD14-perCPCy5.5 and analyzed on the FACSAria ﬂow
cytometer. Only those samples containing a sufﬁcient number of
viable PBMCs (N40% viability as determined by a live–dead marker)
were analyzed.
Statistical analysis
The student's t test and JMP software (version 5.0.1.2; SAS Institute)
was used to analyze comparisons of the expression of intracellular
DEN antigen as well as of cellular markers on the surface of PBMCs
obtained from children with conﬁrmed acute DF versus DHF. The
expression of these markers in primary versus secondary DEN dengue
infection was also compared in a similar manner.
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